Olanzapine

Generic Name
Olanzapine
Brand Names
Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
Drug Type
Small Molecule
Chemical Formula
C17H20N4S
CAS Number
132539-06-1
Unique Ingredient Identifier
N7U69T4SZR
Background

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...

Associated Conditions
Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Associated Therapies
-
Clinical Trials
Related News

A Neuroimaging Investigation of Brain Activity in Major Depressive Disorder and Bipolar Disorder

First Posted Date
2005-09-16
Last Posted Date
2013-02-08
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
42
Registration Number
NCT00188942
Locations
🇨🇦

University Health Network - Toronto General Division, Toronto, Ontario, Canada

🇨🇦

University Health Network - Toronto Western Division, Toronto, Ontario, Canada

Open-Label Comparative Study of Risperidone Versus Olanzapine Versus Quetiapine for Mania in Children and Adolescents With Bipolar I and Bipolar II Disorder

Phase 4
Completed
Conditions
Bipolar Spectrum Disorder
First Posted Date
2005-09-16
Last Posted Date
2013-06-13
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
106
Registration Number
NCT00182013

Olanzapine in the Treatment of Hair Pulling (Trichotillomania)

Phase 4
Completed
Conditions
Trichotillomania
First Posted Date
2005-09-16
Last Posted Date
2006-09-11
Lead Sponsor
Hamilton Health Sciences Corporation
Target Recruit Count
34
Registration Number
NCT00182507
Locations
🇨🇦

Hamilton Health Sciences, McMaster University Medical Centre, Hamilton, Ontario, Canada

Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents

Not Applicable
Terminated
Conditions
Bipolar Disorder
Psychotic Disorders
First Posted Date
2005-09-16
Last Posted Date
2014-01-08
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
68
Registration Number
NCT00183612
Locations
🇺🇸

Cambridge Health Alliance, Medford, Massachusetts, United States

🇺🇸

McLean Hospital, Belmont, Massachusetts, United States

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients

First Posted Date
2005-09-16
Last Posted Date
2015-06-10
Lead Sponsor
University of California, Los Angeles
Target Recruit Count
107
Registration Number
NCT00183625
Locations
🇺🇸

West Los Angeles Veterans Healthcare Center, Los Angeles, California, United States

🇺🇸

Greater Manchester Mental Health Center, Manchester, New Hampshire, United States

Long-Term Olanzapine Treatment in Children With Autism

Phase 2
Completed
Conditions
Autism
Interventions
Drug: Olanzapine
First Posted Date
2005-09-16
Last Posted Date
2014-08-15
Lead Sponsor
Drexel University
Target Recruit Count
32
Registration Number
NCT00183404
Locations
🇺🇸

Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States

6-Month Extension Trial of Asenapine With Olanzapine in Negative Symptoms Patients Who Completed the First 6- Month Trial (A7501014)(COMPLETED)(P05772)

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Drug: asenapine
Drug: olanzapine
First Posted Date
2005-09-15
Last Posted Date
2022-02-09
Lead Sponsor
Organon and Co
Target Recruit Count
196
Registration Number
NCT00174265

Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study

Phase 4
Completed
Conditions
Bipolar Disorder
First Posted Date
2005-09-15
Last Posted Date
2005-09-15
Lead Sponsor
University of Pittsburgh
Target Recruit Count
60
Registration Number
NCT00177567
Locations
🇺🇸

University of Pittsubrgh Medical Center, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
Interventions
Drug: Olanzapine
Drug: Clozapine
First Posted Date
2005-09-15
Last Posted Date
2015-04-07
Lead Sponsor
Harvard Medical School (HMS and HSDM)
Target Recruit Count
38
Registration Number
NCT00169065
Locations
🇺🇸

Commonwealth Research Center, Jamaica Plain, Massachusetts, United States

Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784)

Phase 3
Completed
Conditions
Schizophrenia
Interventions
Other: Placebo
Drug: Asenapine
Drug: Olanzapine
First Posted Date
2005-09-12
Last Posted Date
2022-02-16
Lead Sponsor
Organon and Co
Target Recruit Count
260
Registration Number
NCT00156091
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy